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Abstract
Background: c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by the MET
proto-oncogene. Aberrant activation of c-Met resulting from MET amplification and c-Met overexpression is
associated with poor clinical outcome in multiple malignancies underscoring the importance of c-Met signaling in
cancer progression. Several c-Met inhibitors have advanced to the clinic; however, the development of inhibitory
c-Met-directed therapeutic antibodies has been hampered by inherent agonistic activity.
Method: We generated and tested a bivalent anti-c-Met monoclonal antibody ABT-700 in vitro for binding potency
and antagonistic activity and in vivo for antitumor efficacy in human tumor xenografts. Human cancer cell lines and
gastric cancer tissue microarrays were examined for MET amplification by fluorescence in situ hybridization (FISH).
Results: ABT-700 exhibits a distinctive ability to block both HGF-independent constitutive c-Met signaling and
HGF-dependent activation of c-Met. Cancer cells addicted to the constitutively activated c-Met signaling driven
by MET amplification undergo apoptosis upon exposure to ABT-700. ABT-700 induces tumor regression and tumor
growth delay in preclinical tumor models of gastric and lung cancers harboring amplified MET. ABT-700 in combination
with chemotherapeutics also shows additive antitumor effect. Amplification of MET in human cancer tissues can be
identified by FISH.
Conclusions: The preclinical attributes of ABT-700 in blocking c-Met signaling, inducing apoptosis and suppressing
tumor growth in cancers with amplified MET provide rationale for examining its potential clinical utility for the
treatment of cancers harboring MET amplification.
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Background
Amplification of the MET gene, with consequent c-Met
receptor tyrosine kinase (RTK) overexpression and consti-
tutive kinase activation, is an oncogenic driver in multiple
malignancies [1–4]. Unlike other oncogene RTKs includ-
ing the ERBB family members which have been clinically
targeted with therapeutic antibodies, the development
of inhibitory c-Met-directed therapeutic antibodies has
been challenging [3, 5–7]. Binding of c-Met by HGF or
overexpression of c-Met on cell surface independent of
ligand induces dimerization and activation of the recep-
tor tyrosine kinase [2, 8]. Previously reported bivalent
antibodies generated against c-Met often mimic HGF,
promoting productive dimerization and activation of c-
Met [9, 10]. The engineered monovalent antibody, Met-
MAb (onartuzumab), avoids this agonistic activity [11]
but the monovalent nature of MetMAb may limit the
scope of its activity to HGF-dependent c-Met signaling,
similar to the HGF-binding antibodies [6].
ABT-700 is a bivalent humanized IgG1 that displays
distinctive properties compared to other c-Met-targeting
antibodies. ABT-700 binds cellular c-Met and disrupts
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its productive dimerization and activation induced by
HGF or by the high density of c-Met on the cell surface
independent of ligand. We hypothesize that ABT-700
might be effective in treating cancers harboring ampli-
fied MET and focused preclinical studies to assess its an-
titumor activity in models driven by MET amplification.
These findings provide scientific rationale for the clinical
activity observed in patients with MET amplified tumors
following treatment with ABT-700.
Methods
Antibodies, reagents and cell culture
ABT-700, an anti-human c-Met antibody derived from the
mAb 224G11 [12] was produced in a stable CHO line. Fab
and F(ab)’2 of mAb224G11 (ABT-700) were generated by
digestion with papain or pepsin as described in the litera-
ture [13]. Control human IgG was purchased from Sigma
(I4506). 5D5 mouse anti-human c-Met antibody, the paren-
tal bivalent antibody from which the single armed antibody
onartuzumab was derived, was purified from hybridoma
supernatant (ATCC #HB11895). The anti-c-Met antibody,
LY2875358, was expressed in and purified from HEK293
cells using amino acid sequences derived from published
patent application US201012936. The c-Met tyrosine kinase
inhibitor, PF-4217903, was purchased from Selleck (Catalog
No.S1094). Recombinant human c-Met extracellular
domain with a histidine tag (rh-c-Met ECD-6His) was
expressed in and purified from HEK293 cells. HGF was
purchased from R&D (rhHGF, #294-HGN/CF). The
tumor cell lines A549 (ATCC #CCL-185), EBC1 (JCRB
#0820), Hs746T (ATCC #HTB-135), and OE33 (Sigma
#96070808) were maintained in DMEM (Gibco-Invitrogen
cat. No. 11995) supplemented with 10 % fetal bovine
serum (FBS) (HyClone SH30070.03). IM95 (JCRB #1075)
were also maintained in DMEM, 10 % FBS with 10 mg/L
insulin. SNU5 (ATCC #CRL-5973), NCI-H441 (ATCC
#HTB-174), NCI-H1993 (ATCC #CRL-5909), MKN45
(JCRB 0245), SNU620 (KCLB #00620), and SNU638
(KCLB #00638) were cultured in RPMI-1640 (Gibco-
Invitrogen, cat. No. 11875) supplemented with 10%
FBS. MCF7 cells (ATCC HTB-22) were infected with
control lentivirus or lentivirus containing human c-Met
cDNA in pLVX-IRES-puro vector (Clontech). Stable clones
overexpressing human c-Met protein indicated by Western
Blot and FACS were isolated. These cells were grown in
DMEM (Gibco-Invitrogen cat. No. 11995) supplemented
with 10 % fetal bovine serum (FBS) (HyClone SH30070.03)
and 2 μg/mL puromycin (Sigma). All cell lines were
expanded in culture upon receipt and cryopreserved to
provide cells at similar stage passages for all subsequent
experiments. For cell lines not authenticated in the 6
months before use, c-Met expression was confirmed by
FACS analysis. Information of additional cell lines is
summarized in Additional file 1: Table S1.
Binding ELISA
96-well plates (Costar #3369) were coated with 100 μL/
well of mouse anti-His antibody (Invitrogen #37-2900) at
1 μg/mL in PBS pH7.4 at 4 °C overnight, and then blocked
using Superblock (Pierce, #37535) for one hour at room
temperature. Plates were washed 4 times with PBST and
then incubated with 100 μL of recombinant human c-Met
extracellular domain (rh-c-Met ECD-6His) at 2 μg/mL in
10 % Superblock in PBST for 1 h at room temperature.
Plates were washed 4 times with PBST and then incubated
with ABT-700 or control human IgG in serial dilutions in
10 % Superblock in triplicate wells at room temperature
for 1 h. Plates were washed 4 times with PBST and then
incubated with 100 μL of 1:15,000 goat anti-human
IgG-HRP (Thermo-scientific Pierce, Cat#31412) at room
temperature for 1 h. Plates were washed 4 times in PBST
and 100 μL of TMB (Pierce, #34028) was added to each
well and incubated at room temperature until color devel-
oped (approximately 10 min). Reactions were stopped by
addition of 2N sulfuric acid (Mallinckrodt chemicals,
Cat#H381-05) and optical density (OD) was read at
450 nm.
FACS analysis
For cellular c-Met binding studies, cells were harvested
from flasks when approximately 80 % confluent using Cell
Dissociation Buffer (Invitrogen #13151-014 or #13150-
016). Cell viability was checked by trypan blue staining to
ensure >90 % live cells. Cells were washed once in PBS/1
% FBS (FACS buffer) then resuspended at 1.5-2.5 × 106
cells/mL in FACS buffer. Cells were added to a round bot-
tom 96-well plate (BD Falcon #3910) at 100 μL/well. Ten
μL of a 10x concentration of ABT-700 or controls in du-
plicate wells was added and plates were incubated at 4 °C
for four hours. Wells were washed twice with FACS buffer
then resuspended in 50 μL of 1:500 anti-human IgG Ab
(AlexaFluor 488, Invitrogen #11013) diluted in FACS buf-
fer. Plates were incubated at 4°C for one hour then washed
twice with FACS buffer. Cells were then resuspended in
100 μL of PBS/1 % formaldehyde and analyzed on a
Becton Dickinson LSRII flow cytometer. FACS binding
studies were performed for each cell line in at least two in-
dependent experiments.
For Annexin V apoptosis detection, tumor cells were
plated at 300,000 cells/ well in 12-well dishes in 2 ml
serum-free media (RPMI, 0.1 % BSA). Cells were incu-
bated overnight at 37 °C, 5 % CO2. Cells were treated with
control hIgG (Sigma I4506) and ABT-700 at 10 μg/ml for
24 h. Cells were transferred from 12-well plate into 1.5 ml
microcentrifuge tubes, pelleted, and washed with cold
PBS. Cells were resuspended in 0.1 ml 1X Binding Buffer
provided in kit (BD Pharmingen kit cat# 556547). 5 μl of
FITC Annexin V and 5 μl propidium iodide (PI) were
added and cells were incubated in the dark for 15 min.
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400 μl of 1X Binding Buffer was added and cells were ana-
lyzed on a Becton Dickinson LSRII flow cytometer within
one hour.
Determination of cellular c-Met phosphorylation and total
level
A549 cells were plated at 40,000 per well in 96-well plate
in growth media. Twenty four hours later, cells were pre-
treated with antibodies in duplicate wells for one hour at
37 °C, and then stimulated with HGF for 10 min at 37 °C.
1 nM (~100 ng/mL) HGF was used to stimulate c-Met as
described in the literature [11]. For SNU5 cells that have
constitutively phosphorylated c-Met, the cells were plated
at 20,000 per well in 96-well V-bottom plate in serum free
medium. Twenty four hours later, cells were treated with
antibodies in duplicate wells for six hours at 37 °C. Media
were then removed and cells were lysed with 100 (for
A549) or 150 (for SNU5) μL/well of Cell Lysis Buffer (Cell
Signaling Technology #9803) supplemented with protease
inhibitor tablet (Roche #11714900). ELISA capture plates
were generated by pre-coating wells with 100 μL of an
anti-c-Met antibody (R&D systems, # MAB3581) at 2 μg/
mL) at 4 °C overnight, followed by blocking with 200 μL/
well PBS/1 % BSA treatment for one hour at room
temperature, and washed three times in PBST. Cell lysates
were added to capture plates and incubated at 4°C over-
night. Plates were washed 3 times in PBST, and incubated
with anti-phospho-tyrosine 4G10-HRP conjugate (Milli-
pore #16-105; 1:1000 diluted in PBST + 1 %BSA) for 2 h
at room temperature. To determine total c-Met, second-
ary anti-c-Met HRP conjugate was used. Plates were
washed 3 times in PBST and 100 μL of TMB was added to
each well and incubated at room temperature until color
developed. Reactions were stopped by addition of 100 μL/
well 2N sulfuric acid, and the OD was read at 450 nm.
These studies were performed for each cell line in at least
two independent experiments.
Western blot analysis
Cells were plated at 300,000 per well in 12-well tissue cul-
ture plates and were incubated overnight in growth media.
Cells were incubated with ABT-700 or control for the time
points as indicated at 37 °C. Cells were then lysed with 100
μL/well of 2X LDS NuPAGE sample buffer (Invitrogen
NP0007) with reducing reagent (Invitrogen NP0009). Cell
lysates were resolved by SDS-PAGE using 4-12 % Bis-Tris
NuPAGE gels (Invitrogen NP0322) and transferred to
PVDF membranes (Millipore Immobilon-FL # IPFL07810).
Blots were blocked with Odyssey Blocking Buffer (LI-COR
# 927-40000) for one hour at room temperature, washed
three times with PBST, and then incubated overnight with
appropriate primary antibodies at 4 °C. Following overnight
incubation with primary antibodies, blots were washed
three times with PBST for ten minutes, and then incubated
with either AlexaFluor680 goat anti-rabbit IgG (Invitro-
gen A21109, 1:10000) or goat anti-mouse IRDye 800CW
(Odyssey # 926–32210, 1:5000) for one hour at room
temperature. Blots were then washed three times with
PBST, and visualized by scanning using an LI-COR Instru-
ment Odyssey (Model # 9120). Primary antibodies in-
cluded mouse anti-c-Met (Cell Signaling # 3148 or #
3127), rabbit anti-phospho-Y1234 c-Met (Cell Signal-
ing Technology, # 3077), phosphor-PLCr (Cell Signaling
#2821) , phosphor-Erk (Invitrogen #44680G), phosphor-
Bad (Cell Signaling #9291), total bad (Cell Signaling #9292),
Bim (Cell Signaling #2819), Bcl-xL (BD #51-6646GR), cyto-
chrome C (BD Pharmingen Cat 556433), cleaved PARP
(Epitomic #1074-1), and mouse anti-actin (Sigma, #
A5441). At least two independent experiments were
carried out for each cell line.
Cytochrome C release assay
SNU5 cells (4×106) were treated with control hIgG or
ABT-700 for 24 h. Cells were washed in PBS, pelleted and
resuspended in 50–100 μL Digitonin Lysis buffer (75 mM
NaCl, 8 mM Na2HPO4, 1 mM NaH2PO4, 1 mM EDTA,
350 μg/mL digitonin, and 250 mM sucrose) by pipetting
up and down, and incubated for 30 s. Cells were pelleted
at high speed in microcentrifuge for 1 min, supernatant
(cytosolic fraction) was collected and 2x NuPAGE sample
buffer was added for Western analysis. Pellets (organelle-
containing membrane fraction) were washed in cold PBS
3 times, and lysed by sonication in 1x NuPAGE sample
buffer for Western analysis. The study was performed in
two independent experiments.
Proliferation assay
Tumor cells were plated in 96-well plate (Falcon 35–3075)
in 180 μL growth media at 3000–5,000 cells/well. The
cells were incubated overnight at 37 °C with 5 % CO2. On
Day 2, dilutions of testing articles were added to the cell
plate (20 μL/well) in triplicate wells. Untreated control
wells (for 0 % control) and wells treated with 10 μM staur-
osporin (for 100 % kill) were included in each plate. The
plates were incubated for 3–5 days at 37 °C with 5 % CO2.
To quantify live cells, media was removed and 1x Cell
Titer Aqueous One Solution (Promega, G3581) diluted in
Opti-mem media (Invitrogen # 31985–070) was added to
plates and the plates were then incubated for one hour at
37 °C. The OD at 490 nm was read on a M5 Spectramax
plate reader (Molecular Probes). Percent inhibition was
calculated based on 100 % kill and untreated control wells
using the following formula: 100x (0 % control - treated)/
(0 % control - 100 % kill). For cells grown in suspension
such as SNU5, cells were plated in 96-well plate in 180 μL
medium at 10,000 cells/well and incubated overnight at
37 °C with 5 % CO2. The same protocol as above was
used for treatment and data processing except live cells
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were detected by adding forty μL of Cell Titer Aqueous
One Solution to each well and the plates were then in-
cubated for one hour at 37 °C. The experiments were
repeated at least twice for each cell line.
Anti-tumor efficacy studies in vivo
Studies with gastric (SNU5 and SNU620), lung (EBC1,
NCI-H441) and glioblastoma (U87MG) were carried out
at Pierre Fabre. Animal Ethical Committee was registered
under the CEA-CIPF-108 number. All experiments con-
formed to the United Kingdom Co-ordinating Committee
on Cancer Research (UKCCCR) Guidelines for the Wel-
fare of Animals in Experimental Neoplasia UKCCR for
animal care and use. SCID mice were from Charles River
Laboratories (L’Arbresle, France). Athymic Nude Mice
were acquired from Harlan (Gannat, France). All animals
were housed on a 12 h light/dark cycle, in sterilized filter-
topped cages, in a temperature 22 +/−2 °C and in humid-
ity (30 to 70 %) controlled room. Mice were maintained in
sterile conditions with food and water provided ad libitum
and manipulated according to French and European
guidelines. Animals were examined before the initiation of
experiments to ensure that they were healthy and accli-
mated to the laboratory environment.
Cells (5–10 × 106) were implanted s.c. into the right
flank region of mice. Tumor bearing mice were size
matched and randomized into study groups (n = 5 or 6 as
shown in figure legends). Each experiment consisted of an
ABT-700 dose evaluation injected i.p. compared to con-
trols. Evaluation of the anti-tumor activity was determined
by measuring tumor volume twice a week using the for-
mula: π/6 × length × width × height.
For the ectopic EBC1 lung metastasis and survival model,
mice were injected s.c. with 7x106 EBC1 cells on D0, and
after 5 days, when tumor volume reached 60 mm3 to 80
mm3, mice were size matched and randomized into groups
(n = 7) for treatment with ABT-700 or control adminis-
tered by i.p. injections every 21 days. From D5 to D21,
tumor volume was monitored twice a week with an elec-
tronic caliper. On day 21, subcutaneous primary tumors
were resected from mice anesthetized with a Ketamine/
Xylazine mixture (70/30) injected intra-muscularly. ABT-
700 antitumor activity was monitored by following animal
mortality.
Additional animal groups were introduced for the gastric
xenograft model SNU5 in order to evaluate pharmacody-
namic markers by immunohistochemistry as described in
detail in Additional file 2: Supplementary methods.
Experiments with the gastric Hs746T s.c. xenograft
model were conducted at AbbVie in compliance with Abb-
Vie’s Institutional Animal Care and Use Committee and
the National Institutes of Health Guide for Care and Use
of Laboratory Animals guidelines in a facility accredited by
the Association for the Assessment and Accreditation of
Laboratory Animal Care. SCID mice were obtained from
Charles River (Wilmington, MA). Mice were acclimated to
the animal facilities for a period of at least one week prior
to commencement of experiments.
Hs746T cells (2 × 106) were inoculated in the flanks
of male SCID mice and tumor-bearing animals were
size matched and randomly assigned to cohorts to a
mean tumor volume of approximately 225 mm3 per group
(N = 10) 15 days post inoculation of cells. Dosing for all
agents was initiated on day 16. ABT-700 (10 mg/kg) was
administered twice a week i.p. while docetaxel (7.5 mg/kg)
was administered i.v. as a single dose. A human IgG con-
trol antibody was used as a negative control agent. Tumor
dimensions were determined twice weekly and volume de-
termined with the formula (L x W2)/2.
Fluorescence in situ hybridization (FISH) analysis
MET gene copy numbers in cell lines, tumor xenografts
and human tumor tissue specimens was detected with a
probe mix (Vysis LSI MET SpectrumOrange/Vysis CEP
7 SpectrumGreen, Abbott Molecular) using protocols
described in detail in Additional file 2: Supplementary
methods.
Statistical analysis
Results are expressed as the mean ± SEM. All data were
analyzed with GraphPad Prism V6.05 (GraphPad Soft-
ware, Inc., San Diego, CA). The difference in tumor
growth between different groups was analyzed by two-way
ANOVA Turkey’s multiple comparison tests. The survival
data were analyzed using Log-rank (Mantel-Cox) test.
A P value <0.05 was considered significant.
Results
Characterization of ABT-700 binding properties
ABT-700 is a humanized bivalent IgG1/kappa monoclo-
nal antibody derived from the m224G11 mouse hybrid-
oma [12]. ELISA and FACS-based assays were used to
characterize the binding properties of ABT-700. In an
ELISA format, ABT-700 binds recombinant human c-Met
with an apparent affinity of 0.22 nM (Table 1). Similar
binding to cynomolgus monkey derived c-Met was also
observed although there was no detectable binding to
mouse derived c-Met (not shown). These binding proper-
ties are similar to those observed for the parental mAb
m224G11 [12].
FACS analysis was used to compare the binding of ABT-
700 to human tumor cell lines that express c-Met or harbor
MET amplification. ABT-700 shows monophasic and satur-
able binding to cell lines expressing endogenous c-Met in-
cluding A549, IM95, SNU5 and EBC1 with EC50 values of
0.2 – 1.3 nM (Table 1). There was no ABT-700 binding to
the c-Met negative MCF7 breast cancer cell line, however
following transfection to introduce endogenous c-Met
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expression into this cell line, significant ABT-700 bind-
ing was observed (Fig. 1a and Table 1). These results
indicate specific and high affinity binding of ABT-700
to human c-Met.
ABT-700 antagonizes c-Met signaling in both HGF-
dependent and -independent settings
To determine the effect of ABT-700 on cellular c-Met
phosphorylation induced by exogenous ligand HGF (1 nM)
and/or by over-expressed c-Met in the absence of added
HGF, we used ELISA-based assays to quantify phospho-c-
Met in cell lysates of A549 and SNU5. ABT-700 and par-
ental mAb m224G11 blocked the HGF-induced c-Met
phosphorylation of A549 tumor cell line with an IC50 of 1.0
nM (Fig. 1b). 5D5, the parent murine monoclonal antibody
of MetMAb [11], was also effective in blocking HGF-
induced c-Met phosphorylation (Fig. 1b) although in the
absence of HGF it can induce c-Met phosphorylation and
agonistic activity (see section below). In contrast to the
HGF-dependent A549 cell line, SNU5 gastric cancer cells
express high levels of constitutively phosphorylated c-Met.
ABT-700 treatment, but not 5D5 treatment (data not
shown), caused more than 80% reduction of phosphory-
lated c-Met in SNU5 cells with an IC50 of 0.4 nM (Fig. 1c).
ABT-700 also caused a decrease of total cellular c-Met by
~40 % in this cell line (Fig. 1d). Given that the decrease of
c-Met phosphorylation was greater than that of c-Met pro-
tein, inhibition of phosphorylation and down-regulation of
receptor may be caused through distinct mechanisms by
ABT-700. The antagonistic activity of ABT-700 required
the bivalent nature of the antibody because the Fab
fragment did not inhibit c-Met phosphorylation or in-
duce c-Met down-regulation (Fig. 1c and d).
Activation of c-Met tyrosine kinase induces phosphoryl-
ation of receptor adaptor proteins such as Gab1, triggering
Akt and Erk signaling cascades [2, 3, 14]. Treatment with
the agonistic c-Met antibody 5D5 mimics activity of the
native ligand HGF that induces elevating levels of
phosphorylated Gab1, Akt and Erk in both the HGF
ligand-dependent U87MG and the MET constitutively ac-
tivated Hs746T cells after treatment (Fig. 1e). In contrast,
ABT-700 and its parental mouse hybridoma antibody
m224G11 antagonize cellular c-Met signaling without
causing agonist activity as evidenced by a decrease in
phosphorylated signaling molecules including Gab1, Akt
and Erk in both cell lines (Fig. 1e).
ABT-700 activity differs from the recently reported anti-
c-Met antibody LY2875358 [15] in tumor cells where
c-Met signaling can be driven by both receptor expression
and HGF stimulation. SNU620 gastric cancer cells have
high basal level of phosphorylated c-Met as shown in
Fig. 1f, and their growth in vitro is stimulated by the agon-
istic anti-c-Met antibodies 5D5 (Fig. 1f). Similar effects on
cell proliferation were also observed after treatment with
HGF (data not shown). ABT-700 showed more robust in-
hibition of c-Met signaling and proliferation in SNU620
cells than LY2875358 although the latter was similarly
effective (not shown) in other cellular models examined
for ABT-700 as shown in Fig. 1. This difference was seen
also in efficacy trials in vivo where ABT-700 but not
LY2875358 inhibited the SNU620 tumor growth (de-
scribed in sections below).
Taken together, these data suggest that ABT-700 is a
differentiated anti-c-Met antibody with strong antagon-
istic effect on both HGF-independent constitutive c-Met
signaling and HGF-dependent activation of c-Met.
ABT-700 induces apoptosis in cell lines harboring MET
amplification
To identify tumor lines with aberrant c-Met signaling suit-
able for further examination of the effect of ABT-700, we
evaluated a panel of 35 human cancer cell lines for MET
amplification, c-Met protein expression and their depend-
ence on c-Met activity for growth in vitro. Most of the cell
lines evaluated were derived from gastric cancer because of
the high incidence of MET amplification associated with
that cancer type [16, 17]. As summarized in Table 2 and
Fig. 2a, we identified eight tumor cell lines exhibiting MET
gene amplification as determined by fluorescent in situ
hybridization (FISH) with an average ratio of MET and
CEP 7 (a centromere control) copy numbers of 2 or greater
(Table 2 and Additional file 3: Figure S1). All cell lines
harboring MET amplification except for NCI-H1573
showed dependence on c-Met signaling for growth in
vitro (Table 2). NCI-H1573 cells do not have high level of
c-Met protein despite possessing low level amplification of
the MET gene (Table 2). On the other hand, there are cell
lines that do not have MET amplification but show c-Met
signaling dependence likely due to the presence of auto-
crine HGF (e.g. IM95) and/or c-Met overexpression (e.g.
SNU638 and NCI-H820).
Table 1 Binding affinity of ABT-700
ABT-700 (nM)
Biding to c-Met protein by ELISAa 0.22







aEC50 values were derived from an ELISA in which c-Met ECD was captured on
the plate via a histidine tag. Value shown is averages of 6 experiments
bEC50 values were derived from FACS analysis of ABT-700 on various cell lines.
Values are representative of at least two experiments
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The SNU5 gastric cancer cells harboring MET amplifi-
cation and constitutively activated c-Met signaling was
selected for further analysis to compare ABT-700 and
antibody 5D5. The SNU5 cells contained an average of
20 copies of MET with a MET/CEP 7 ratio of 2.6 (Fig. 2b
and Table 2) and high levels of total and phosphorylated
c-Met protein (Fig. 2c). The IM95 gastric cancer cell line
was included for comparative analysis since it exhibits
autocrine HGF signaling [18] and dependence on c-Met
signaling in the absence of MET amplification (Fig. 2a and
Additional file 3: Figure S1). ABT-700, but not 5D5, inhib-
ited the proliferation of the MET amplified SNU5 cells,
whereas both ABT-700 and 5D5 inhibited the growth of
the HGF-driven IM95 cells (Fig. 2d). These results dem-
onstrate that only ABT-700 blocked both amplification-
driven (HGF-independent) and HGF-dependent c-Met
activation. The antagonistic activity of ABT-700 against
the constitutively activated c-Met requires bivalent bind-
ing because the Fab fragment of ABT-700 does not inhibit
proliferation (Fig. 2e), consistent with the effects on c-Met
phosphorylation observed in these cells (Fig. 1c).
Given that ABT-700 inhibited SNU5 cell growth by
more than 90%, we further examined its effect on c-Met
signaling pathways and induction of apoptosis in these
cells. SNU5 cells possess constitutively activated c-Met as
indicated by the high levels of phosphorylated c-Met
(Fig. 2c and f). ABT-700 treatment down-regulated c-Met,
and abrogated the level of phosphorylated c-Met and
downstream signaling molecules including PLCγ, and Erk
(Fig. 2f). ABT-700 treatment also activated the intrinsic
apoptosis machinery resulting from the imbalance of
pro- and anti-apoptotic proteins such as Bad and Bcl-
xL. Phosphorylation of Bad leads to its ubiquitylation
and degradation [19]. ABT-700 induced a decrease of
phosphorylated Bad and the consequent stabilization of
this pro-apoptotic protein, which was accompanied by
elevation of the pro-apoptotic Bim and a decrease of
the anti-apoptotic Bcl-xL (Fig. 2f ). Other events consist-
ent with the activation of the intrinsic apoptosis pathway
were detected in the ABT-700 treated cells, including the
release of cytochrome C into the cell cytoplasm and cleav-
age of the DNA repair enzyme, poly ADP ribose polymer-
ase (PARP) (Fig. 2f). The increase in Annexin V staining
of SNU5 cells following ABT-700 treatment further con-
firmed the occurrence of apoptosis (Fig. 2g). Furthermore,
induction of apoptosis by ABT-700 was seen in other cell
lines with amplified MET including SNU620 gastric can-
cer and EBC1 NSCLC but not in Hs746T and MKN45
gastric cancer cells (data not shown). Collectively, these
results demonstrate that ABT-700 can inhibit the prolifer-
ation and consequently induce apoptotic cell death in can-
cer cells addicted to c-Met signaling driven by MET
amplification.
ABT-700 inhibits tumor growth in models driven by MET
amplification
Next we examined the effects of ABT-700 on tumor growth
of subcutaneously implanted human tumor xenografts har-
boring amplified MET. ABT-700 inhibited the growth of
established SNU5 tumors harboring amplified MET at
doses ranging from 2.5 to 40 mg/kg, with long-term tumor
regressions including complete responses observed at doses
of ≥ 10 mg/kg (Fig. 3a). ABT-700 decreased both total and
phosphorylated c-Met and the downstream signaling pro-
teins, phosphorylated Akt and Erk, as measured by immu-
nohistochemistry from treated tumor tissue collected on
day 7 and/or 21 after a single dose at 10mg/kg (Fig. 3b).
Cell proliferation in tumor tissue, indicated by Ki67 stain-
ing, was suppressed at both time points (Fig. 3b). These
pharmacodynamic responses correlated with activity of in-
hibition of tumor growth; ABT-700 at doses below 5 mg/kg
was not effective in inhibiting the tumor growth or the sig-
naling proteins (Additional file 4: Figure S2). ABT-700 also
inhibited the growth of four additional human tumor
(See figure on previous page.)
Fig. 1 ABT-700 specifically binds cellular c-Met and antagonizes c-Met signaling in both HGF-dependent and -independent settings. a FACS analysis of
ABT-700 binding to MCF7 transfectants. Stable human c-Met or vector control transfectants of human MCF7 breast cancer cells were incubated with
increasing amounts of ABT-700 and bound ABT-700 was detected by FACS with secondary anti-human IgG conjugated with Alexa 488. b ELISA
quantification of phospho-c-Met in A549 cells. A549 cells grown in a 96-well plate were pre-incubated for one hour with antibodies in a dose-range as
shown, followed by stimulation with 1 nM HGF for 10 min. Total cell lysates were made and phospho-c-Met was detected by ELISA. c ELISA
quantification of phospho-c-Met in SNU5 cells. SNU5 cells grown in a 96-well plate were incubated with antibodies in a dose-range as shown for 6 h.
Total cell lysates were made and subjected to ELISA for phospho-c-Met. The value of cells in media alone was used as 100 % of control. d ELISA
quantification of total c-Met in SNU5 cells. SNU5 cells grown in a 96-well plate were incubated with antibodies in a dose-range as shown for 6 h.
Total cell lysates were made and c-Met level was determined by ELISA. The value of cells in media alone was used as 100 % of control. e Western blot
analysis of U87MG cell lysates. U87MG cells grown in a 12-well plate were treated with antibodies as shown at 10 μg/mL for 10 min, 1 h or 6 h. Total
cell lysates were analyzed for c-Met and other phosphorylated targets as shown. Western blot analysis of Hs746T cell lysates. Hs746T cells grown in a
12-well pate were treated with antibodies as shown at 10 μg/mL for 6 h. Total cell lysates were analyzed for c-Met and other phosphorylated targets
as shown. f Western blot analysis of SNU620 cell lysates. SNU620 cells grown in a 12-well pate were treated with antibodies as shown at 10 μg/mL for
24 h. Total cell lysates were analyzed for c-Met and other phosphorylated targets as shown. g Inhibition of proliferation of SNU620 cells. SNU620 cells
were plated in a 96-well plate and treated with antibodies in a dose range as shown for 3 days. Quantification of live cells at the end of incubation
was done with Cell-titer Glo reagents. The data shown in all panels are from one of at least two independent experiments showing similar results as
described in Methods
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xenografts harboring MET amplification including EBC1
NSCLC and SNU620, Hs746T and MKN45 gastric cancer
(Fig. 3c and 3d; and ref. [12]). Furthermore, ABT-700 was
effective in prolonging survival in an EBC1 metastasis
model (Fig. 3e). These results indicate that ABT-700 ef-
fectively antagonizes constitutively activated c-Met and
Table 2 Summary of MET status and sensitivity to ABT-700 in a panel of 35 human cancer lines











Max Inhibition by (%)
PF-4217903b ABT-700c
SNU620 gastric KCLB 41.6 4.4 10.6 6.7 56 95 80
H1993 lung ATCC 32 11.9 2.8 5.4 829 50 30
Hs746T gastric ATCC 22.2 3.9 6.6 6 377 55 40
OE33 esophageal Sigma 21.4 6.9 3.1 6 430 60 70
SNU5 gastric ATCC 20.2 7.9 2.6 12 910 95 90
EBC1 lung JCRB 15.6 3.1 5.2 6 374 85 30
MKN45 gastric JCRB 12.6 3.4 4 10 297 96 50
H1573 lung ATCC 11.5 4.3 2.7 1.8 5 0 0
H2342 lung ATCC 8.6 5.2 1.7 0.7 1.3 0 0
H820 lung ATCC 8.3 5 1.7 2.9 5.7 20 0
NUGC-2 gastric JCRB 7.8 8.2 1 0.5 0.1 0 0
FU97 gastric JCRB 7.6 7.5 1 0.1 0.1 0 0
NUGC-4 gastric JCRB 6 5.1 1.3 1 15 50 0
SNU-16 gastric ATCC 5.1 5.7 0.9 0.5 2.5 0 0
KATOIII gastric ATCC 4.6 5 0.9 0.9 16 0 0
SNU-216 gastric KCLB 4.5 4.7 1 0.8 0.5 0 0
MKN-1 gastric JCRB 4.4 3.8 1.2 0.2 0.1 0 0
SNU-484 gastric KCLB 4.2 4 1 0.1 0.1 0 0
SNU-668 gastric KCLB 3.6 3.6 1 1.9 0.5 0 0
SNU-1 gastric ATCC 3.3 3.2 1 NA NA 0 0
RERF-GC-1B gastric JCRB 3.1 4.2 0.8 0.6 0.6 0 0
OCUM-1 gastric JCRB 3 2.9 1 0.4 0.3 0 0
SCH gastric JCRB 3 3.5 0.9 0.3 0 0 0
NCC-StC-K140 gastric JCRB 2.8 9 0.3 0.5 0.3 30 0
SNU-719 gastric KCLB 2.7 3.5 0.8 0.4 0.1 0 0
IM95 gastric JCRB 2.5 2.5 1.1 0.2 0.5 90 60
MKN74 gastric JCRB 2.4 2.6 1 0.1 0.1 0 0
SNU-601 gastric KCLB 2.4 3 0.8 0.4 2.6 0 0
U87MG glioblastoma ATCC 2.1 2.1 1 0.5 3 30 30
23132/87 gastric DSMZ 2 1.9 1.2 0.5 0.2 0 0
AGS gastric ATCC 2 2.2 1 0.2 0.1 0 0
NUGC-3 gastric JCRB 2 3.2 0.7 0.5 1.1 0 0
SNU638 gastric KCLB 2 2 1 3.6 28 80 50
TAKIGAW gastric JCRB 2 5.1 0.4 0.4 0.1 0 0
NCI-N87 gastric ATCC 1 2 0.5 NA NA 0 0
A549 lung ATCC NA NA NA 1 1 0 0
aNormalized to actin and relative A549 which was assigned 1
bat 1 μM concentration that is known to fully inhibit cellular c-Met with minimal off-target effect [21, 28]
cat 10 μg/mL (~67 nM) that saturates c-Met binding
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downstream signaling leading to inhibition of tumor growth
in preclinical tumor models withMET amplification.
We also investigated whether ABT-700 in combination
with established therapies would provide additional thera-
peutic benefit in preclinical animal models. In the MET-
amplified Hs746T gastric cancer model, the combination
of ABT-700 with docetaxel, an anti-mitotic microtubule
inhibitor clinically used for gastric cancer, was more effica-
cious than either agent given as monotherapy (Fig. 4a).
Although ABT-700 or docetaxel monotherapy at near
maximal tolerated dose inhibited tumor growth in this
model, the longer duration of response observed following
combination therapy suggests that this combination may
be a useful clinical strategy for delaying tumor relapse. A
similar outcome was observed in NSCLC models where
combination of ABT-700 and standard of care chemothera-
peutics such as the nucleoside analog gemcitabine or the
anti-mitotic drug vinorelbine (Navelbine) at near maximal
tolerated doses. ABT-700 alone effectively suppressed the
EBC1 tumor growth but was not able to induce complete
responses (Figs. 3c and 4b). Single agent gemcitabine
was also only partially effective (Fig. 4b). Combination
of these two agents produced tumor regressions and
eradications (Fig. 4b). In the NCI-H441 NSCLC xeno-
graft model that is known to have overexpression of
c-Met with gene amplification [20] (Fig. 4c), combin-
ation of the ABT-700 parental mAb m224G11 with




Fig. 2 ABT-700 inhibits proliferation and induces apoptosis in MET amplified tumor cells. a MET status and dependence in a panel of 35 human
cancer lines. Average of MET/CEP7 was calculated in 20 random cells and the red symbol indicates cell lines harboring MET amplification (MET/
CEP 7 ratio ≥2). MET dependence was indicated by the maximal inhibition of proliferation of each cell line grown under regular medium
containing FBS by the selective c-Met kinase inhibitor PF-4217903 at 1 μM for 3 days. Additional details are summarized in Table 1. b Image of
FISH analysis of MET in SNU5 cells. Red represents signal of MET while green represents CEP 7. FISH images of additional cell lines are shown in
Additional file 3: Figure S1. c Immune-blots of total and phosphorylated c-Met protein from total cell lysate of A549 and SNU5 cells as described
in the legend of Fig. 1. d and e Inhibition of SNU5 proliferation. SNU5 cells were plated in 96-well plate and treated with antibodies or antibody
fragments in a dose range as shown for 3 days. Quantification of live cells at the end of incubation was done with Cell-titer Glo reagents. Data
are from one representative experiment. f Immune-blots of signaling and apoptosis pathway molecules in SNU5 cells treated with 10 μg/mL
ABT-700 for 24h as described in the legend of Fig. 1. g Dual PI and Annexin V FACS analysis of SNU5 cells treated with 10 μg/mL ABT-700 for
24h. The percent of Annexin V positive apoptotic cells is shown. Data are from one experiment that was reproduced in independent experiments
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control of tumor growth. U87MG is an aggressive gli-
oma that possesses autocrine HGF c-Met signaling [21].
mAb m224G11 suppressed U87MG tumor growth
demonstrating single agent activity against this HGF-
dependent tumor (Fig. 4d). The current SOC therapy
for GBM is radiation treatment in combination with
the DNA alkylating agent, temozolomide (TMZ), although
novel treaments that extend patient survival are urgently
needed [22]. Addition of TMZ at near maximal tolerated
dose to m224G11 therapy in the U87MG glioma xeno-
graft model resulted in enhanced anti-tumor effects com-
pared to either agent alone (Fig. 4d). Because neither the
NCI-H441 nor the U87MG tumor models is MET ampli-
fied, these results suggest that ABT-700 in combination
with existing therapies may broaden177 the clinical indi-
cations beyond those tumors with MET amplification to
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Fig. 3 ABT-700 shows antitumor activity in preclinical models of tumor xenografts of human cancer cells harboring MET amplification. a Tumor
growth curves of SNU5 gastric cancer treated with ABT-700. SCID mice with established tumors were treated with ABT-700 in a dose response
administered by intra-peritoneal injections every 21 days. Each group had 6 mice; all ABT-700 treatment groups show significant difference
(P value <0.0001 indicated by ****) when compared to the control group (day 4–28); high dose (10–40 mg/kg) groups are significant different
from 5 mg/kg group (P value <0.0001 indicated by ++++) for day 4–63. b IHC analysis of SNU5 tumors treated with ABT-700. As in (a), tumors
from mice treated with a single dose of ABT-700 at 10 mg/kg or vehicle control for 7 or 21 days were harvested and subjected to IHC analysis for
markers as indicated. Representative images of one tumor are shown. c Tumor growth curves of EBC1 tumor xenograft model. SCID mice with
established tumors were treated with ABT-700 in dose response administered by intra-peritoneal injections every 21 days. Each group had 5 mice;
all ABT-700 treatment groups show significant difference (P value <0.0001 indicated by ****) when compared to the control group (day 4–31);
high dose (20–40 mg/kg) groups are significant different from 10 mg/kg group (P value <0.0001 indicated by ++++) for day 4–42. d Tumor
growth curves of SNU620 gastric cancer treated with ABT-700. SCID mice with established tumors were treated with ABT-700 in dose response
administered by intra-peritoneal injections every 21 days. Each group had 6 mice; all ABT-700 treatment groups show significant difference
(P value <0.0001 indicated by ****) when compared to the control group (day 4–28); there was no significant difference among treatment
groups (day 4–28). e Survival curves of mice with metastatic EBC1 tumors treated with ABT-700. Primary tumors established after subcutaneous
inoculation of EBC1 cells were surgically removed and ABT-700 at 10 mg/kg, Q21D, was administered with several schedules (start and end day)
as shown. Growth of metastases in the lung caused death of animals and mortality was monitored over 530 days. Each group had 7 mice; comparison
of survival curves by Log-rank (Mantel-Cox) test showed significance with P value <0.01 indicated by ** or <0.05 indicated by * as compared to the
control group
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MET amplification in gastric cancers and potential clinical
utility of ABT-700
MET gene amplification ranging from frequencies of 1-20%
has been documented in a variety of human cancers, in-
cluding liver metastases from colon carcinoma [23], non-
small cell lung carcinomas with acquired resistance to
EGFR inhibitors [24] and gastric cancers [16, 17]. A MET
FISH assay was developed for detecting MET gene amplifi-
cation in human biopsied cancer tissues utilizing a probe
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Fig. 4 Combination of ABT-700 and chemotherapies exhibits enhanced antitumor activity in preclinical tumor models. a Tumor growth curves of
Hs746T gastric cancer treated with ABT-700 in combination with docetaxel. ABT-700 at 10 mg/kg was administered twice a week for the duration of
the experiment either alone or in combination. Docetaxel at a dose of 7.5 mg/kg was administered once at the start of dosing either alone or in
combination. A human IgG control antibody was used as a negative control agent for ABT-700. Each group had 10 mice; there was no significant
difference among the vehicle and isotype control groups; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when
compared to the control groups (day 4–11); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or docetaxel
single agent and the combination group (day 4–28). b Tumor growth curves of EBC1 xenografts treated with ABT-700 in combination
with gemcitabine. Athymic mice with established tumors were treated with ABT-700 at 20 mg/kg by i.p. injections every 21 days during
the course of study either alone or in combination. Single dose of gemcitabine at 138.5 mg/kg was given on day 0 either alone or in
combination. Each group had 5 mice; all treatment groups showed significant difference (P value <0.0001 indicated by ****) when compared to the
control groups (day 6–24); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or gemcitabine single agent and
the combination group (day 6–51). c Tumor growth curves of NCI-H441 NSCLC treated with m224G11 in combination with Navelbine. Athymic nude
mice with established tumors were treated i.p. either with a loading dose of 2 mg of antibody/mouse and then twice a week with 1 mg of antibody/
mouse until Day 33 either alone or in combination. Navelbine was dosed (on D0, D7, and D14) at 8 mg/kg by i.p. injections either alone
or in combination. A third group administered with the combination treatment was also included. Each group had 6 mice; all treatment
groups showed significant difference (P value <0.0001 indicated by ****) when compared to the control groups (day 3–36); there was a significant
difference (P value <0.0001 indicated by ++++) between ABT-700 or navelbine single agent and the combination group (day 3–58). d Tumor growth
curves of U87MG glioma treated with m224G11 in combination with TMZ (temozolomide). Athymic nude mice with established tumors were treated
i.p. with a loading dose of 2 mg of antibody/mouse and then twice a week with 1 mg of antibody/mouse until Day 33 either alone or in combination.
TMZ was given (on D0, D7, and D14) at 5 mg/kg by i.p. injections either alone or in combination. A third group administered with the
combine treatment was included. Each group had 6 mice; all treatment groups showed significant difference (P value <0.0001 indicated
by ****) when compared to the control groups (day 4–14); there was a significant difference (P value <0.0001 indicated by ++++) between ABT-700 or
TMZ single agent and the combination group (day 4–35)
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located on the chromosome locus 7q31.2. This MET FISH
assay was applied to a tissue microarray of 140 human
gastric cancer samples obtained from Asian patients. As
anti-HER2 antibody is indicated for the treatment of HER2
positive gastric cancer, we also performed HER2 FISH ana-
lysis. MET amplification as defined by MET/CEP7 ratio ≥2
was seen in 10% of 134 evaluable patient samples, and 9 of
the 13 MET amplified samples were also positive for HER2
amplification (Fig. 5). This data suggest that patients with
HER2 positive gastric cancers should not be excluded from
treatment with c-Met inhibitors although further studies
are required to confirm the co-existence of amplification of
MET and HER2 in this disease setting. Together with earl-
ier studies [16, 17], the data suggest thatMET amplification
may represent a critical genetic aberration in gastric can-
cers and this patient population could benefit from treat-
ment with ABT-700.
Discussion
MET amplification is associated with poor prognosis in a
variety of cancers highlighting the significant unmet med-
ical need of this patient population. We describe preclin-
ical results that justify the clinical investigation of ABT-
700 in cancer types with addiction to the MET oncogene.
In a phase 1 clinical trial in patients with advanced solid
tumors [25], ABT-700 was well tolerated and the mono-
therapy at the recommended dose of 15 mg/kg demon-
strated anti-tumor activity in patients with MET amplified
solid tumors [26]. By RECIST, 3 of 5 patients with tumors
harboring MET amplification, as determined by FISH, had
a partial response (1 each ovarian, gastric and esopha-
geal). Among these 3 patients, the duration of response
was 19, 23, and 24 weeks, respectively [26]. This study
has been expanded to enroll additional patients with
MET amplification and to better define predictive bio-
markers, safety and clinical benefit.
The tumor cell lines evaluated in our study herein
that harbor MET gene amplification, as defined by
FISH analysis, and overexpress c-Met protein, are sen-
sitive to ABT-700. Cancer cells addicted to constitutively
activated c-Met undergo apoptosis upon exposure to ABT-
700 monotherapy leading to tumor regression in preclin-
ical animal models. Our data emphasizes the need for a
patient selection strategy that harbor MET amplification as
they most likely would benefit from ABT-700 treatment.
Ultimately, ABT-700 may have broader clinical utility as
the prevalence of MET amplified tumors increases with
disease progression, recurrence and/or treatment regi-
mens [1–4]. Thus, acquiring fresh tumor biopsies for
FISH analysis may be needed to identify patients with
MET amplification. Recently somatic splice site alterations
at MET exon 14 (METex14) that result in exon skipping
and MET activation were described in human cancers
[27]. Although we have not included METex14 analysis in
our studies, it will be important to establish the clinical
relevance of these genetic aberrations.
In addition to inhibiting tumors with MET gene ampli-
fication, ABT-700 also inhibits the subcutaneous xeno-
graft growth of human tumor cell lines that have c-Met
protein overexpression or autocrine HGF. Patients with
tumors driven by HGF-dependent c-Met activation may
benefit from combination of ABT-700 with chemother-
apy. In this context, the demonstration of more robust
and sustainable anti-tumor activity in animal models
following the combination of ABT-700 with different
standard of care cytoreductive chemotherapies provides
the basis for exploration of effective combination ther-
apy in the clinic.










Fig. 5 MET amplification as detected by FISH analysis in human gastric cancer specimens. a Venn diagram showing amplification frequency in a
tissue microarray of gastric cancer samples of Asian patients. MET amplification was defined as average of MET/CEP 7 ratio ≥2 in chromosomally
abnormal cells selected for enumeration. HER2 amplification was defined similarly but with the ratio of HER2/CEP 17≥ 2. b Composite image of a
MET amplified gastric cancer sample. Insert shows clusters of amplified MET genes in the nuclei of tumor cells
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ABT-700 is among the first reported bivalent anti-c-Met
antibodies that lack agonistic activity [12, 15]. By inhibit-
ing both ligand-dependent and c-Met overexpression-
induced signaling in broad types of cancer cells, ABT-700
differentiates from other therapeutic agents targeting the
HGF/c-Met axis [6, 7, 11] including the recently disclosed
antagonistic IgG4 c-Met targeting antibody LY2875358
[15]. ABT-700 binds a unique epitope on c-Met outside
the Sema domain which 5D5 recognizes [11, 12] and
antagonizes c-Met signaling in a variety of cancer cells in-
cluding SNU620 gastric cancers where LY2875358 dem-
onstrated no in vivo antitumor activity. Since ABT-700
contains a humanized IgG1 heavy chain, antibody effector
functions may also contribute to its antitumor activity. Re-
sults from in vitro ADCC functional assays indicate that
ABT-700 can mediate the lysis of cellular targets by hu-
man natural killer cells (data not shown).
Conclusions
ABT-700 shows preclinical activities in blocking both
HGF-dependent and HGF-independent c-Met signaling,
inducing apoptosis and suppressing tumor growth in can-
cers with amplified MET. Collectively, the attributes of
ABT-700 coupled with early signs of activity in a phase 1
clinical trial support investigation of this antibody, as
monotherapy and in combination, in malignancies charac-
terized by aberrant activation of c-Met signaling including
cancers harboringMET amplification.
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